Biotrial S.A., a leading clinical research organization based in France that provides drug discovery and developmental services worldwide, announced today the purchase of approximately 1.2 acres in University Heights Science Park (UHSP) on which it plans to build its North American headquarters.UHSP recently completed the sale of the land in an area bounded by New, Norfolk and Newark Streets.
Architecture firm Francis Cauffman has completed the master design plan for the facility and expects to break ground in the spring of 2013. Biotrial is anticipating occupying the building early in 2014.
Biotrial’s arrival in Newark marks another significant step in the continuing evolution of a mixed use technology park in the Science Park section of Newark’s Central Ward, a strategy to drive economic development for the continued revitalization of the area. UHSP is a collaborative venture supported by the adjacent education institutions – the University of Medicine and Dentistry of New Jersey (UMDNJ), Rutgers-Newark, NJIT and Essex County College – City, State and Federal government, private industry and community groups. Thus far, a total of 351,000 square feet of office, research and technology space; a daycare center; and 21 units of owner-occupied housing have been developed within Science Park, and more than 90 incubating companies are located there. The UHSP initiative also developed nearby Science Park High School in partnership with the Newark Public Schools district.
The Biotrial initiative strongly supports a goal of the 23-member UHSP Board of Trustees to spur economic development through the creation of a range of jobs and the generation of purchasing power.
The new facility will become the North American headquarters for Biotrial, which manages more than 80 drug trials and studies annually, many within its own facilities in France and the United Kingdom. It is anticipated that the Biotrial project will create 150-200 construction jobs initially and eventually more than 100 permanent healthcare jobs to support the permanent Biotrial operation in Newark.
The Science Park leadership has enthusiastically endorsed Biotrial’s establishing a major research center here, citing potential opportunities for new significant scientific and economic benefits for Newark and throughout New Jersey. The leadership also expressed its praise for Lt. Governor Kim Guadagno for her assistance in attracting Biotrial to the Park.
Joel Bloom, president of NJIT and chairman of the Science Park Board of Trustees, said, “This is a significant milestone for Science Park. Achieving this commitment from Biotrial continues the momentum for developing a world-class science and technology center in Newark. It is especially exciting for the Greater Newark community to have this major commitment from Biotrial to build its North American headquarters here. Simply put, this means hundreds of construction jobs and permanent jobs to follow, and greatly enhanced purchasing power impacting the surrounding communities, which address the primary goals of the Science Park leadership team.”
Jean-Marc Gandon, president and chief executive offer of Biotrial, commented: “To expand in North America, we needed proximity to superior research and medical facilities and to a major transportation center. We looked at many locations around the world before deciding that Newark and University Heights Science Park best meet the many key requirements and standards we have for conducting our research.”
Denise V. Rodgers, MD, interim president of the University of Medicine and Dentistry of New Jersey and vice chair of the Science Park Board of Trustees, noted, “We anticipate Biotrial’s new headquarters here will spark a series of collaborations with the pharmaceutical and biotech industries to advance learning, discovery and innovation. Further, this will focus more attention on Newark, the State and the region as a research center, attracting the best in the biomedical and health sciences and advancing leading edge interventions to improve health outcomes locally and around the world.”
President Edith Abdullah, Essex County College, said that Biotrial is “an applications company that gives our region’s college students experiential education opportunities through internships as well as creates research opportunities for the Newark-based universities’ PhD students.”
Rutgers-Newark Interim Chancellor Phil Yeagle remarked, “Biotrial creates an opportunity for the significant numbers of biologists and other life sciences researchers and educators that are members of our Newark faculties.”
Worldwide, Biotrial provides a wide range of services, including Phase I studies, clinical trial management of Phase II, III and IV studies, data management, biostatistics, ECG and imaging core laboratory, medical writing, non-clinical pharmacology, regulatory affairs counseling, drug evaluation and pharmacology research services. Its primary areas of drug therapy research include: allergy, cardiovascular, CNS, dermatology, endocrinology/metabolism, gastroenterology, hematology, immunology, infectious diseases, oncology, respiratory, rheumatology, and women’s health.